Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 RC5.2 | DOI: 10.1530/endoabs.81.RC5.2

1Police Medical Centre of Thessaloniki, Department of Endocrinology, Thessaloniki, Greece; 2Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; 3Cardiology Clinic, Hippokration General Hospital, Athens, Greece; 4Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece; 5Aristotle University of Thessaloniki, 1st Propedeutic Department of Internal Medicine, Medical School, Thessaloniki, Greece; 6Cardiology Clinic, University General Hospital of Heraklion, Heraklion, Greece; 7Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou General Hospital Thessaloniki, Thessaloniki, Greece; 82nd Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece; 9Cardiometabolic Center, Lipid Clinic, LA apheresis Unit, Metropolitan Hospital, Athens, Greece; 10Department of Internal Medicine, 424 General Military Training Hospital, Thessaloniki, Greece; 11Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, B’ Pediatrics Clinic, General Children’s Hospital “Pan. & Aglaia Kyriakou”, Athens, Greece; 122nd Propedeutic Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Thessaloniki, Greece; 13Department of Internal Medicine, General Hospital of Goumenissa, Goumenissa, Greece; 141st Propedeutic Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece


Aims: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in the general population. However, such a role in patients with familial hypercholesterolemia (FH) is less documented. The purpose of this study was to evaluate the association between Lp(a) concentrations and ASCVD prevalence in adult patients with FH.

Methods: This was a cross-sectional study from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Patients were categorized into 3 tertiles according to Lp(a) levels.

Results: A total of 541 adult patients (249 males) with possible/probable/definite FH heterozygous FH (HeFH) were included (mean age 48.5±15.0 years at registration, 40.8±15.9 years at diagnosis). Median (interquartile range) Lp(a) concentrations in the 1st, 2nd and 3rd Lp(a) tertile were 6.4 (3.0-9.7), 22.4 (16.0-29.1) and 77.0 (55.0-102.0) mg/dl, respectively. There was no difference in lipid profile across Lp(a) tertiles. The overall prevalence of ASCVD was 9.4% in the first, 16.1% in the second and 20.6% in the third tertile (P=0.012 among tertiles). This was also the case for premature ASCVD, with prevalence rates of 8.5%, 13.4% and 19.8%, respectively (P=0.010 among tertiles). A trend for increasing prevalence of coronary artery disease (8.3%, 12.2% and 16.1%, respectively; P=0.076 among tertiles) was also observed. No difference in the prevalence of stroke and peripheral artery disease was found across tertiles.

Conclusions: Elevated Lp(a) concentrations are significantly associated with increased prevalence of ASCVD in patients with possible/probable/definite HeFH.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.